Compare Illinois Tool Works Inc. (ITW) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illinois Tool Works Inc. vs Tango Therapeutics Inc. — how do they compare? Illinois Tool Works Inc. trades at $271.34 (market cap $75.85B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: Illinois Tool Works Inc. is far larger — about 20.2× Tango Therapeutics Inc.'s market cap, and Illinois Tool Works Inc. pays a 2.58% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Illinois Tool Works Inc. for 66 Days and Tango Therapeutics Inc. for 0 Days on average.
| ITW | TNGX | |
|---|---|---|
Market Cap | $75.85B | $3.75B |
Volume | 960,368 | 9,619,106 |
Sector | Industrials | Health |
52-Week High | $299.60 | $32.90 |
52-Week Low | $241.07 | $7.50 |
Typical Hold Time | 66 Days | 0 Days |
Enterprise Value | $84.70B | $2.77B |
Dividend Yield | 2.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ITW trades at $269.47, up 1.64% with consistent earnings beats in recent quarters. The stock shows bearish technical signals but maintains strong fundamentals with 19.39% net margins and 104.65% ROE. Recent dividend increase to $1.72 reinforces its Dividend King status with 59 years of growth. Revenue stability around $16B and operational cash flow exceeding $3B demonstrate business resilience despite mixed analyst sentiment.
Outlook remains balanced with upside to $276.86 consensus target but faces headwinds from elevated P/E of 24.12 and bearish technical momentum. The company's disciplined capital allocation and sector diversification provide stability, though automotive and foodservice weaknesses present near-term challenges. Valuation appears full given current growth rates.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Illinois Tool Works Inc.
Illinois Tool Works is a diversified global manufacturer that produces specialized industrial equipment, consumables, and related services. The firm operates 87 global divisions through seven distinct operating segments: automotive OEM, construction products, food equipment, specialty products, test/measurement and electronics, polymers and fluids, and welding. About half of its revenue comes from its operations in North America, with the remainder originating from international markets. ITW takes a bottom-up and decentralized approach to portfolio management, with the exception that each segment must apply its 80/20 operating process modeled on the Pareto principle.
Read more on ITW →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
